Skip to main content
To the Editor: We appreciate Dr. Diller’s thoughtful letter, which emphasizes clinical recommendations regarding stimulant prescribing, especially the importance of minimizing immediate-release stimulants that appear to be the most misused formulations. We provide some additional information to address this topic. The purpose of our recently published article was to simultaneously examine the prevalence and correlates of overall prescription stimulant use, misuse, use disorders, and motivations for misuse in the U.S. adult population (1). The 2015 and 2016 National Surveys on Drug Use and Health include immediate-release methylphenidate and amphetamine as well as multiple other formulations (Table 1). The full list of medications (along with pill images) are provided as a memory aid during the survey interview. However, analyzing specific formulations is not recommended because of potential recall bias and reporting errors by respondents who may not recognize the subtle labeling differences. Some researchers have reported that for adults with attention deficit hyperactivity disorder (ADHD), immediate-release methylphenidate is an effective treatment (2), and immediate-release amphetamine is as effective as sustained-release amphetamine (3). Researchers also have reported that among adults ages 18–49, the prevalence of nonmedical use is much higher for immediate-release than extended-release ADHD medications (4). We agree with Dr. Diller that the clinical indications for prescribing immediate-release stimulants for treating ADHD need to be better specified. Future research should examine the use, misuse, use disorders, and motivations for misuse of immediate-release methylphenidate and amphetamine among both youths and adults in the United States.
TABLE 1. Prescription stimulant subtypes assessed in the 2015 and 2016 National Surveys on Drug Use and Health
SubtypeControlled Substances Act ScheduleComments
Amphetamine productsIISubtype includes Adderall, Adderall XR, Dexedrine, Vyvanse, generic dextroamphetamine, generic amphetamine-dextroamphetamine combinations, generic extended-release amphetamine-dextroamphetamine combinations, or similar products that respondents specified for past-year misuse. Vyvanse is included because its active ingredient (lisdexamfetamine) is metabolized to dextroamphetamine.
Methylphenidate productsIISubtype includes Ritalin, Ritalin SR, Ritalin LA, Concerta, Daytrana, Metadate CD, Metadate ER, Focalin, Focalin XR, generic methylphenidate, generic extended-release methylphenidate, generic dexmethylphenidate, generic extended-release dexmethylphenidate, and any other stimulant containing methylphenidate that respondents specified for past-year misuse.
Anorectic (weight-loss) stimulantsIII or IVSubtype includes Didrex, benzphetamine, Tenuate, diethylpropion, phendimetrazine, phentermine, or similar products that respondents specified for past-year misuse. Didrex, benzphetamine, and phendimetrazine are schedule III controlled substances. Tenuate, diethylpropion, and phentermine are schedule IV controlled substances.
ProvigilIVThe active ingredient is modafinil. The drug is prescribed to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, or shift-work disorder.
Any other prescription stimulantIncludes use or misuse of stimulants containing other active ingredients.

References

1.
Compton WM, Han B, Blanco C, et al: Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. Am J Psychiatry 2018; 175:741–755
2.
Kocher J, Adams P: Immediate-release methylphenidate for the treatment of ADHD in adults. Am Fam Physician 2015; 91:445–446
3.
Castells X, Blanco-Silvente L, Cunill R: Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018; 8:CD007813
4.
Cassidy TA, Varughese S, Russo L, et al: Nonmedical use and diversion of ADHD stimulants among U.S. adults ages 18–49: a national Internet survey. J Atten Disord 2015; 19:630–640

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 77 - 78
PubMed: 30848946

History

Accepted: 24 September 2018
Published online: 1 January 2019
Published in print: January 01, 2019

Keywords

  1. Stimulant Abuse
  2. ADHD
  3. CNS Stimulants
  4. Epidemiology
  5. Psychoactive Substance Use Disorder

Authors

Details

Wilson M. Compton, M.D., M.P.E. [email protected]
National Institute on Drug Abuse, Bethesda, Md. (Compton, Blanco); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Han, Jones).
Beth Han, M.D., Ph.D.
National Institute on Drug Abuse, Bethesda, Md. (Compton, Blanco); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Han, Jones).
Carlos Blanco, M.D., Ph.D.
National Institute on Drug Abuse, Bethesda, Md. (Compton, Blanco); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Han, Jones).
Christopher M. Jones, Pharm.D., M.P.H.
National Institute on Drug Abuse, Bethesda, Md. (Compton, Blanco); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Han, Jones).

Notes

Send correspondence to Dr. Compton ([email protected]).

Competing Interests

The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, and the U.S. Department of Health and Human Services.

Funding Information

The authors’ disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share